Vectura Share Discussion Threads

[boadicea] 01/6/2020 12:28

We would also have to overtake 888 Holdings.

[justiceforthemany] 01/6/2020 11:45

GSK will be happy to keep us out of the FTSE250...why not just make an offer of say £1Bn and be done with it?

[polaris] 01/6/2020 11:15

I'm back to 80 k here. I'm trying to reposition the portfolio, but the spread on some of my other positions isn't conducive to cashing in.

VEC volume is very low today, suggests the buyback has yet to kick in. I'll be interested to see how trading picks up when the US opens, as well as over the current trading week as the new buyback starts. I new spreadsheet is ready...

Pretty sure CMC will get the last available FTSE250 place, assuming DGOC doesn't qualify for entry.

[pooroldboy55] 01/6/2020 11:07

Hi PAUL
I must say your optimism is eternal
i have just 30000 of these now and will hang on in there, but waiting for good news from VEC is a like death it will happen one day for sure but when !!!!!!!!!!!
Cheers all.
POB

[polaris] 01/6/2020 09:50

I was also looking at that last night. There are a few companies near the auto exit level too that might tip the scales. It's going to be close, that is for sure. Oh for the acceptance of VR315 to come this afternoon or tomorrow... ;-)

[jimboyce] 01/6/2020 09:42

Not such a bad thing if we don't make it this time, with the new buy back starting today. Perhaps we could enter next time round, which would suit long termers.

[boadicea] 01/6/2020 08:54

The chance of 250 entry seems to be slipping away. We would have needed ~95p last Friday in order to beat CMC Markets for the final place. However it's close enough for a determined big player to manipulate it whichever way they want - by close tomorrow.

Rule quote:
"The index reviews will be based on data from the close of business on the Tuesday before the first Friday of the review month. Any constituent changes will be implemented after the close of business on the third Friday of the review month.

[base7] 28/5/2020 17:59

Surely our Fluti revenues,margins & profits from Japan cover our current MV with all else in for free,including our current cash pile,which continues to grow.

[polaris] 28/5/2020 14:33

Been waiting for the Kyorin FY to finally be posted - expected on 12/5. Seen them today.

FY20 Flutiform sales (to end March 2020) 14.6 Bn Yen cf. 13.1 Bn Yen.

sales growth over last several years:
7.2-10.1-11.9-13.1-14.6 Bn Yen.

Forecast for FY21 15 Bn Yen.

Still awaiting decision from Japanese health authorities on application to expand indication to pediatric patients.

VEC take manufacturing AND royalties for sales.

Conversion is £110 M in sales up to March 2020 cf. £99 M in previous year.

[justiceforthemany] 28/5/2020 14:32

Same pattern every day - opens high by a few pence then drip sell throughout the day to finish flat/red...clear market tricks and manipulation.

[base7] 27/5/2020 19:46

Always the near term hope for positive news regarding approval of our Advair generic ,which together with the resumption of our buy back next Monday will hopefully underpin our share price & perhaps a stronger clue as to the types of & scale of the deals our new senior management team have been busily working on

[polaris] 27/5/2020 19:08

pdoc - potentially awarded. None of the 10 M shares are currently in circulation. They are set aside for LTIP and other awards that are dependent on performance.

Buybacks are not there to pump up the share price They are there to increase EPS, due to cash on balance sheet being ignored by market in valuation of company. They also reduce free float.

On the FTSE250 question, VEC are currently in, as there are some real dogs in the FTSE250 that are well below the automatic exit ranking. I think VEC will make it as long as they stay above around £520 M market cap, and possibly as low as £500 M.

[pdoc] 27/5/2020 17:57

Buy-back won't help much. The last buy-back was all awarded to the Board and Senior Management in various investment plans - almost to the penny.

[pooroldboy55] 27/5/2020 15:24

Well as we are not expecting any no problem there.
And if its anything like last time it will only push the price down more. Buy back that is and any good news

[jimboyce] 27/5/2020 14:37

Best for us LTH's is to keep a lid on any good news until the company has acquired a further £10 m worth of our shares.

[base7] 27/5/2020 07:58

I am not a lawyer so cant interpret although,worryingly,their arguments sound worthy of further consideration .It would be interesting to know whether the lawyers for GSK genuinely believe they ere likely to win in the event of a re trial or whether they view their chances,at best, at 50/50 & this just posturing in order to try for an out of court settlement.
AGM trading update contained nothing earth shattering,either way , but being on target in these tricky times with much progress in respect of business development is very encouraging, along with the resumption of the share buy backs-all of which will hopefully ensure that our share price holds/increases & we gain entry into the 250

[a1ord53] 27/5/2020 07:52

Anybody knows how to participate AGM today ?

[a1ord53] 27/5/2020 06:35

Couldnt post all GSK YESTERDAYS REPLY, here table of content and Conclusion:

ARGUMENT .............................................................................................................4
I. VECTURA FAILED TO PRESENT SUBSTANTIAL EVIDENCE THAT
GSK’S COMMERCIAL PRODUCTS MEET THE DISPERSION
LIMITATION ......................................................................................................4
A. Vectura Failed To Show That Study 2 Could Properly
Control For Increased Dispersion Even Among Its
Experimental Blends .............................................................................4
B. Vectura Failed To Show That Study 2’s Experimental
Blends Were Representative Of GSK’s Commercial
Products .................................................................................................8
C. Vectura Presents No Evidence Of Increased Dispersion
For GSK’s Umeclidinium Products ....................................................12
D. Vectura’s Purported Evidence Beyond Study 2 Is Even
Less Relevant ......................................................................................13
E. Vectura’s Failures Of Proof Require Judgment Of Non-
Infringement ........................................................................................16
II. GSK IS ENTITLED TO A NEW TRIAL UNDER THE CORRECT
CLAIM CONSTRUCTION OF “COMPOSITE ACTIVE PARTICLES”........................19
III. GSK IS ENTITLED TO A NEW TRIAL ON DAMAGES .......................................21
A. Vectura’s Improper Jury Argument Justifies A New Trial.................21 1. GSK’s Argument Is Not Waived ..............................................

Case: 20-1054 Document: 29 Page: 4 Filed: 05/26/2020
2. Vectura’s Conduct Was Improper ............................................25
3. Vectura’s Conduct Justifies A New Trial .................................25
B. Vectura’s Disregard Of The Annual Royalty Cap And
Failure To Apportion Independently Supports A New
Trial

201, 1227 (Fed. Cir. 2014). A remand for a new trial is required.

CONCLUSION

For the foregoing reasons, the judgment of infringement should be reversed. In the alternative, the Court should vacate and remand for a new trial on infringement and damages

[justiceforthemany] 26/5/2020 21:03

Vectura is right on the cusp of automatic entry into FTSE 250 which will trigger buying by tracker funds.

[a1ord53] 26/5/2020 19:34

FILED from Appellants GlaxoSmithKline LLC and Glaxo Group Limited. Title: REPLY BRIEF. Service: 05/26/2020 by email. (PENDING COMPLIANCE REVIEW) [696897] [20-1054] [William Lee] [Entered: 05/26/2020 02:32 PM]

[pooroldboy55] 26/5/2020 19:06

Don't think anything to do with GSK more like never seems to be any good news always tomorrow and remember tomorrow never comes with VECTURA

[justiceforthemany] 26/5/2020 17:45

GSK trying to keep this out of the FTSE 250?! Review next Weds.
6% down on a day when markets are surging?

[diesel] 24/5/2020 09:31

Well that’s a first for this thread....

[vecturaking] 24/5/2020 06:34

🎙️
27897;️PODCAST: Hear @venthoye, our EVP Product Development, share her insights on how to identify the best opportunities to repurpose or reposition existing drugs for inhaled administration vectura.podbean.com #inhalation #drugdevelopment #Vectura #CDMO

[vecturaking] 24/5/2020 06:32

Breathing New Life into Existing Drugs
Inhaled
administration has the potential to bring benefits to patients – and commercial success to businesses – across a number of therapeutic spaces.

But how do you identify the best opportunities for drug repurposing or repositioning?
Geraldine Venthoye | 05/20/2020 | Longer Read

Finding new uses for old drugs is now a significant trend in the pharma industry. There can be some inconsistency about terminology, but generally speaking, a repurposing project will take a drug already approved for one indication and seek approval for another or, alternatively, a new formulation may be created to allow administration via a different route for the same indication. A repositioning project, meanwhile, tends to take an existing drug and give it an improved or altered product profile, while keeping the same administration route. Either way, as well as providing advantages for patients, repurposing or repositioning can also be used to extend intellectual property (IP) coverage and drive additional revenue for innovators. Drug repositioning now accounts for almost a third of all new drug products, generating half a trillion dollars in annual sales across all dosage forms (1).

Inhaled administration offers significant repurposing opportunities; only a relatively small number of medicines made their first appearance on the market in inhaled form. A number of drugs that are today very familiar in inhalers started life in another delivery format, including beta-2 agonists, anticholinergics, and corticosteroids, as well as antibiotics, such as tobramycin and aztreonam. Though most are locally effective products – notably those designed to treat respiratory disease – some are systemically targeted, such as drugs to treat diabetes, migraine, or Parkinson’s disease.